Literature DB >> 22460143

Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis.

Seda Yilmaz-Elis1, Annemieke Aartsma-Rus, Anne Vroon, Judith van Deutekom, Sjef de Kimpe, Peter A C 't Hoen, Gert-Jan van Ommen, J Sjef Verbeek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22460143     DOI： 10.1136/annrheumdis-2011-200971

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  Alternative pre-mRNA splicing of Toll-like receptor signaling components in peripheral blood mononuclear cells from patients with ARDS.

Authors:  Rachel Z Blumhagen; Brenna R Hedin; Kenneth C Malcolm; Ellen L Burnham; Marc Moss; Edward Abraham; Tristan J Huie; Jerry A Nick; Tasha E Fingerlin; Scott Alper
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

Review 2.  Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.

Authors:  Linda Yip; C Garrison Fathman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 3.  Self-antigen expression in the peripheral immune system: roles in self-tolerance and type 1 diabetes pathogenesis.

Authors:  Rebecca Fuhlbrigge; Linda Yip
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

4.  Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability.

Authors:  Elizabeth M McNally; Eugene J Wyatt
Journal:  J Clin Invest       Date:  2016-03-21       Impact factor: 14.808

Review 5.  Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.

Authors:  Yoshitsugu Aoki; Matthew J A Wood
Journal:  J Neuromuscul Dis       Date:  2021
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.